Blueprint Medicines Corp (NAS:BPMC)
$ 102.71 -0.92 (-0.89%) Market Cap: 6.43 Bil Enterprise Value: 6.17 Bil PE Ratio: 0 PB Ratio: 20.71 GF Score: 74/100

Blueprint Medicines Corp to Discuss the FDA Approval of GAVRETO Conference Call Transcript

Sep 08, 2020 / 12:00PM GMT
Release Date Price: $70.19 (-3.90%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions). I would now like to hand the conference over to your speaker today, Ms. Kristin Hodous. Thank you. Please go ahead, ma'am.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the FDA approval of GAVRETO. You can access the press release announcing the approval as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.blueprintmedicines.com.

With me on the call today are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christina Rossi, our Chief Commercial Officer.

Before we get started, I would like to remind everyone that statements we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot